Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson & Johnson / Janssen Biotech / Janssen-Cilag / AstraZeneca) and Xtandi (Pfizer / Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). However, the use of second-generation hormonal agents has expanded beyond mCRPC, and they are being positioned in the lucrative nonmetastatic CRPC and metastatic hormone-sensitive settings. The late-phase pipeline for mCRPC has also become more dynamic, with two PARP inhibitors (Johnson & Johnson’s Zejula and Pfizer’s Talzenna), three immune checkpoint inhibitors (Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo, Bristol Myers Squibb / Ono Pharmaceutical’s Yervoy, Merck Sharp and Dohme’s Keytruda), two kinase inhibitors (Array BioPharma / Roche / Genentech / Chugai’s ipatasertib and AstraZeneca’s capivasertib), one radioligand therapy (Novartis’s 177Lu-PSMA-617), and one angiogenesis inhibitor (Exelixis / Takeda / Ipsen’s Cabometyx) in Phase III development.
- What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
- How is prostate cancer currently managed, and how will treatment practices change in the future?
- What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2029?
- What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.
Key companies: Johnson & Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Bayer HealthCare, Clovis Oncology, Merck Sharp & Dohme, Exelixis, Ipsen, Takeda, AstraZeneca, Bristol Myers Squibb, Ono Pharmaceutical, Novartis, Myovant Sciences.
Key drugs: Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Nubeqa (darolutamide), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Cabometyx (cabozantinib), ipatasertib, relugolix, 177Lu-PSMA-617, capivasertib.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.